Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature ‐based meta‐analysis

In conclusion, the expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. RRM1 expression assessment could provide more detailed information for patients with pancreatic cancer and could be used to optimize therapeutic schemes. The expression of RRM1 can be considered a predictor of poor survival in patients with pancreatic cancer receiving gemcitabine chemotherapy. RRM1 expression assessment could provide more detailed information for patients with pancreatic cancer and could be used to optimize therapeutic schemes.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fjcpt.12655

Source: Journal of Clinical Pharmacy and Therapeutics - December 1, 2017 Category: Drugs & Pharmacology Authors: Q. L. Han, Y. H. Zhou, Y. Lyu, H. Yan, G. H. Dai Tags: REVIEW ARTICLE Source Type: research